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The number of patients with implantable elec-tronic devices (IEDs) is growing as indications for
a myriad of cardiac and neurological disorders that
cannot be managed using medication alone expand.1
These devices include gastric and cardiac pacemakers,
implantable cardioverter defibrillators, cochlear
implants, and a range of stimulators of the deep brain,
vagal nerve, sacral nerve, phrenic nerve, spinal cord,
and bone. Encountering patients with an IED who
present for office-based procedures is becoming
increasingly common. Electromagnetic interference
(EMI) during routine procedures has been reported to
be associated with inappropriate functioning of IEDs.2
Adverse effects of performing electrosurgery on
patients with IEDs pose a patient safety risk. Medical
and manufacturer reports have primarily focused on
larger electrosurgical equipment used in hospitals and
their effect on IEDs. Our purpose was to provide a
clinical review of commonly encountered IEDs, their
clinical indications, potential interference with office-
based electrosurgical equipment, and recommenda-
tions to prevent complications and injury.
IEDs: Clinical Indications
Cardiac Pacemakers
Although pacemaker technology has advanced since
the first one was implanted in 1958,3 common
indications are still symptomatic bradyarrhythmias,
such as sinus node dysfunction and heart block. A
pacemaker consists of a battery-powered generator
connected to electronic pacing wires inserted intra-
venously to the right-side chambers of the heart.4
The earliest devices were asynchronous devices,
pacing the heart at a fixed rate regardless of the
patient’s underlying rhythm and sometimes causing
symptomatic hemodynamic consequences. The latest
models are demand pacemakers that sense the heart’s
intrinsic rhythm and inhibit pacing in the same
chamber or trigger pacing in another cardiac cham-
ber.5,6 These devices also have sophisticated timing
features to optimize heart rates and even treat some
atrial arrhythmias.
Implantable Cardioverter Defibrillators
Implantable cardioverter defibrillators (ICDs) have
had a profound effect on patients with ventricular
tachyarrhythmias and those at risk for sudden car-
diac death.7 ICDs are programmed to treat life-
threatening ventricular arrhythmias with rapid
overdrive pacing or an internal defibrillator shock.
These patients most commonly have severe acquired,
inherited, or idiopathic forms of cardiomyopathy.
Indications continue to expand to include asymp-
tomatic patients with low ejection fractions at risk of
sudden death. Similar to pacemakers, these devices
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consist of a pulse generator implanted subcutane-
ously in an infraclavicular pocket and connected to
one or more leads for defibrillation and pacing5
(Figure 1). The generator or battery component of
ICDs and pacemakers requires replacement approx-
imately every 5 years. Some patients with ICDs or
pacemakers receive biventricular pacing or cardiac
resynchronization therapy. These devices have the
additional capability of pacing the right and the left
ventricle through a pacing lead placed through the
coronary sinus. These are used to improve the sur-
vival and symptoms of patients with moderate to
severe congestive heart failure, left ventricular dys-
function (left ventricular ejection fraction o0.35)
and an abnormally wide QRS on electrocardiogram
who remain symptomatic despite optimal heart
failure drug therapy.6,8
Cochlear Implants
A cochlear implant is an option for individuals with
hearing loss when hearing aids provide limited or no
benefit. A cochlear implant system consists of two
main parts. The first is the internal implant consist-
ing of an electronics housing and the electrode array.
The second is the external speech processor (worn
behind the ear) containing a microphone and elec-
tronics to process sound. Additional components
include a cable, a transmitting coil, and a battery
pack.9 An external sound processor captures sound
and converts it into digital signals, which are then
converted into electrical impulses by an internal
implant and sent to an electrode array implanted
into the cochlea.10 Electrical impulses from the
cochlea stimulate the inferior root of the acoustic
nerve. Neural discharges induce auditory sensations
at the level of the brain cortex, restoring partial
hearing.11 Candidates include children aged 12
months and older who have profound bilateral
sensorineural hearing loss and adults with severe to
profound bilateral sensorineural hearing loss who
receive little or no benefit from traditional hearing
aids.9
Deep Brain Stimulators
Deep brain stimulation is a targeted neurosurgical
intervention that enables an implanted pacemaker to
electrically stimulate structures deep within the
brain.1 The system was approved by the FDA in
199712 for use in patients with drug-refractory
essential tremor or Parkinsonian tremor that con-
stitutes a significant functional disability. Deep brain
stimulation is also indicated as an aid in the man-
agement of chronic, intractable primary dystonia,
including generalized and segmental dystonia, hem-
idystonia, and cervical dystonia (torticollis) in indi-
viduals aged 7 and older.13 The device consists of a
lead composed of a thin coiled wire with four elec-
trodes stereotactically implanted in various sites of
the brain. The lead is connected to a thin, insulated,
coiled wire tunneled subcutaneously from the head
and neck to the chest, where it attaches to a pulse
generator implanted in a subcutaneous pocket in the
anterior chest wall. Patients have the ability to turn
the device on or off and switch between settings
using an external magnet.4,14 Targets for stimulation
include the internal globus pallidus, subthalamic
nucleus, and thalamus.1,4,13 Implanting a device at
these sites allows for individualized programming of
stimulator impulse amplitude and frequency for
optimal symptom management.15
Figure 1. Chest radiograph of a patient with an implanted
cardioverter defibrillator. PG, pulse generator; RA, pace-
maker lead in the right atrium; CS, pacemaker lead in the
coronary sinus; RV, defibrillator lead in the right ventricle.
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Vagal Nerve Stimulators
The FDA approved the use of vagal nerve stimulators
for the management of medically refractory epilepsy in
1997.1,12 Since then, indications for the use of these
devices have expanded to include depression.16,17
Additional indications under investigation include
obesity, Alzheimer’s disease, chronic pain syn-
dromes,18 anxiety, bulimia, and migraine headaches.16
Candidates for vagal nerve stimulator implantation
include adults and adolescents aged 12 and older with
partial-onset seizures refractory to medications and
patients aged 18 and older with chronic or recurrent
major depression without adequate response to at
least four antidepressant treatments.17
Vagal nerve stimulators consist of a constant-current
pulse generator, a single subcutaneously placed lead
wire, and a silicone rubber–imbedded platinum
electrode wrapped around the left vagus nerve.18
The implantable, multiprogrammable pulse genera-
tor is housed in a hermetically sealed titanium case
and is powered by a single battery. The lead trans-
mits electrical signals from the pulse generator to the
vagus nerve.19 The left vagus nerve is preferred over
the right because there are more cardiac efferent
fibers from the right vagus nerve, stimulation of which
may result in more-frequent adverse cardiac effects.
Programming of the device occurs by placing an
external programming wand on the skin overlying
the generator. Radio frequency signals communicate
between the generator and software on a standard
personal computer or personal digital assistant.18
Sacral Nerve Stimulators
Sacral nerve stimulation was developed to treat
incontinence in patients with severe neurologic
disease.1,12 In 1997, the device was approved for urge
incontinence and in 1999 for nonobstructive urinary
retention and significant symptoms of urgency fre-
quency refractory to medications and behavioral
therapy.13 Other indications include interstitial
cystitis, pelvic pain, and fecal incontinence. The
device consists of a generator implanted subcutane-
ously in the hip area with a lead wire (containing
four platinum electrodes) surgically inserted into the
sacral foramen at S3 on one side adjacent to the
sacral nerve.1 Patients have the ability to turn the
device on and off using an external control unit.12
Phrenic Nerve Stimulators
A phrenic nerve stimulator provides ventilatory sup-
port for patients with chronic respiratory insufficiency
whose diaphragm, lungs, and phrenic nerves have
residual function.20 Candidates for diaphragm pacing
include, but are not limited to, patients who require
chronic ventilatory support because of central alveolar
hypoventilation, decreased day or night ventilatory
drive (sleep apnea, Ondine’s curse), or brain stem or
spinal cord injury, or disease.21 The pacing system
electrically stimulates the phrenic nerve to cause
rhythmic contraction of the diaphragm.1 It consists of
electrodes sutured to each phrenic nerve, a radio
receiver implanted in a subcutaneous pocket, and an
external battery-powered transmitter and antenna
assembly. The external transmitter and antenna send
energy and stimulus information to the passive
receiver implant, which transmits electrical impulses
to the phrenic nerve by the electrode. The diaphragm
muscle contracts, producing the inhalation phase of
breathing. The transmitter then stops generating sig-
nals, which allows the diaphragm to relax, and
exhalation occurs. This continuous cycle produces a
normal breathing pattern.21
Spinal Cord Stimulators
Spinal cord stimulators aid in the management of
chronic, intractable pain of the trunk and limbs,
including unilateral or bilateral pain refractory to
conservative and surgical interventions often associ-
ated with conditions such as chronic low back pain
syndrome, radiculopathy, postsurgical pain, degen-
erative disk disease or herniated disk, peripheral
causalgia, epidural fibrosis, arachnoiditis, and
complex regional pain syndrome. Spinal cord stim-
ulation involves the delivery of mild electrical
signals to the epidural space. The perception of
paresthesia in the area where pain is felt ‘‘masks’’
pain signals.13 Leads are typically implanted under
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fluoroscopic guidance into the epidural space
adjacent to the lower aspect of the spinal cord be-
tween levels T9 and L1 or open placement in the
cervical region. A generator is usually implanted
anteriorly using a tunneled approach between the
skin and fascial layers.12 Electric current produced
by the pulse generator is transferred to the lead
generating paresthesia. Patients can use an
external programmer to adjust intensity and location
of stimulation within clinician-set parameters to
meet pain management needs.13
Gastric Pacemaker
Gastric electrical stimulation was advocated as a
possible treatment for gastric motor dysfunction as
early as 1963.22 In 2000, the FDA approved the
device for human use for the treatment of chronic
intractable nausea and vomiting secondary to gas-
troparesis of diabetic or idiopathic etiology.1,13,22 In
addition, it is under investigation as an adjuvant
therapy to blunt appetite and reduce food intake in
morbidly obese people.22,23 The device consists of a
small battery-powered neurostimulator implanted in
a subcutaneous pocket of the lower abdominal
region connected to two intramuscular leads im-
planted in the muscle wall of the antrum of the
stomach. A handheld, external programmer non-
invasively adjusts therapy specifically for each
patient, assesses neurostimulator battery status, and
can perform troubleshooting as needed.13 All devices
have a phasic stimulation pattern, with an initial on
time during which a pulse or series of pulse bursts
are administered, followed by an off period without
current delivery. On times range from 0.1 to 4 sec-
onds and off times from 1 to 5 seconds and are set
based on treatment protocols for gastroparesis and
obesity. Parameters such as pulse frequency and
duration can be modified to elicit specific motor and
symptom responses.23 The exact mechanism under-
lying gastric pacing for gastroparesis is not well un-
derstood. It is thought that gastric pacing generates
high-frequency stimuli, which enhance motility and
facilitate emptying.1,12 Gastric stimulation for obe-
sity is thought to augment antral contractions,
enhancing satiety elicited by postprandial gastric
distention.23
Bone Stimulator
Bone has an inherent bioelectrical property gener-
ated by cellular metabolism. Being rich in calcium
phosphate crystals, it also exhibits piezoelectric
properties when subjected to mechanical stress. Both
are thought to be important in modifying a variety of
processes in the callus and remodeling phases of
fracture healing. An understanding of these proper-
ties coupled with an accumulating body of evidence
on the positive effect of electric stimulation on
osteoprogenitor cell production has led to the ap-
plication of electrostimulation to accelerate bone
healing.24 Bone stimulators are used as an adjunct to
planned surgery or when adherence is of concern in
patients with nonunions. They may also be used as
an adjunct to internal and external fixation and
autograft.25 Invasive and noninvasive bone stimula-
tors are available. Noninvasive devices use an elec-
tromagnetic field to stimulate growth and consist of
a generator and electrodes attached to the surface of
the skin. Invasive devices use direct current and
involve the implantation of electrodes at a desired
site for bone growth. Negative electrodes are placed
at the site of bone repair, and positive electrodes are
placed in the soft tissue. A generator is implanted
subcutaneously nearby or in an intramuscular
plane.1 A third, partially invasive method involves
the implantation of one lead into the fracture site
and of a second lead on the skin. The generator is
incorporated into a cast.12
Electrosurgical Equipment
Heat Electrocautery, Nongrounded Monopolar,
Grounded Monopolar, and Bipolar Devices
Most outpatient dermatologic surgery procedures
employ some form of external energy source for
hemostasis. There are two general methods to obtain
hemostasis: electrocautery and electrosurgery. Each
has an electrical power source, but their interference
with IEDs varies, each carrying a different risk to the
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patient, making knowledge of the IED and equipment
selection important. Even though the risk for EMI is
low with many IEDsFdepending on the procedure
and method of hemostasisFthe potential for harm
can be reduced with equipment selection. Thus, pre-
operative evaluation for the office-based dermasur-
geon in patients with IEDs includes the challenge of
balancing adequate hemostasis with the risk of EMI.
Heat electrocautery does not use electric current5,26; it
converts electrical energy at high resistance into ther-
mal energy, heating a metal tip, which produces
hemostasis when held in direct contact with tissue.4
Because no electric current passes to the patient, heat
electrocautery is the safest instrument for hemostasis in
patients with IEDs for office-based procedures when
the risk of EMI is high. Risk of thermal damage to an
implant from direct heat is minimal and only of con-
cern when using the device directly over the IED.4,5
Broadly, electrosurgery is a high-frequency alternat-
ing electrical current through an unheated elec-
trode.26 Two methods of current can be delivered:
monopolar and bipolar. In monopolar electrosur-
gery, current delivered to the surgical site is through
one electrode. High-powered electrosurgical units,
found in hospital operating rooms, are typically
monopolar units, generating current that travels
from the electrode instrument to the surgical site
through the patient’s body to a grounding pad
(return electrode) and back to the electrosurgical
unit to complete a circuit. In contrast, office-based
monopolar electrosurgical units (e.g., Hyfrecator,
Conmed Corp, Utica, NY) are low powered, making
a grounding pad optional. When a grounding pad is
absent, current disperses throughout the body. This
is a relatively safe means of obtaining hemostasis in a
majority of patients and is commonly used for rou-
tine office-based dermatologic procedures, but
because current flows beyond the surgical site, the
use of a low-powered unit without a grounding pad
has the potential to cause interference in patients
with an IED. In bipolar electrosurgery, current
travels through a two-electrode instrument from one
electrode, through tissue, to a second adjacent elec-
trode, completing an electrical circuit. Because cur-
rent through bipolar instruments is concentrated
across the tips, a grounding pad is not required, and
electrical energy capable of interfering with an IED is
minimized4 (Figure 2).
General Considerations
Information regarding the presence or absence of an
IED should be obtained from each patient before
planned procedures such as Mohs, postprocedure
reconstruction, electrodesiccation and curettage,
and standard excisions and biopsies in which
electrosurgery may be used. For unplanned
procedures, verbal confirmation of the presence or
absence of an IED should be obtained from each
patient before performing electrosurgery. Once
identified, preoperative evaluation should focus on
the type of device, its medical indication, type and
extent of procedure, and amount of bleeding
expected. Type and location of IED, date of im-
plantation and last interrogation, programmability,
symptoms when device is turned off, and need for
postoperative interrogation are also important.1 The
type of electrosurgery should be planned based on
the anticipated surgical procedure. Heat electro-
cautery or bipolar instead of monopolar electro-
surgery is favored for unmonitored procedures,
because these are generally safer in patients with
IEDs.27 For procedures of higher complexity,
physicians should also consult the patient’s primary
Figure 2. Electromagnetic interference risk and effective
hemostatic capability of different electrosurgical techniques.
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device specialty physician and consider consulting
an industry representative or device specialist for
additional intraoperative safety measures.
Electrosurgery and Implanted Cardiac Devices
Electrosurgery-associated EMI has resulted in a
small number of inappropriate episodes of device
malfunction, including suspension of arrhythmia
detection and delivery of a defibrillatory shock in
patients with ICDs.6,7,28–32 More-recent reports
suggest that modern cardiac pacemakers have
greater immunity from EMI than earlier devices.2
Despite these advances, the sensing circuitry does not
filter out some types of EMI, which may be errone-
ously interpreted as a rapid heart rate. For instance,
if EMI is persistent, an ICD can misinterpret it as
tachyarrhythmia, resulting in inappropriate delivery
of shock therapy,33 but newer ICDs have incorpo-
rated filters to detect EMI, making this risk very
low.31,34 Surgeons should not fear transmission of
the shock to themselves or others in contact with the
patient because most of the electric force dissipates
before reaching the patient’s skin.35,36
The earliest nondemand pacemakers lacked the
capability to sense electromagnetic signals and are
rarely encountered today,5 but virtually all modern
pacemakers and ICDs are demand devices and could
be affected by EMI. The most commonly encoun-
tered response of demand pacemakers to EMI is
oversensing, resulting in pacing inhibition.28,37–39
Other responses include inappropriately triggered
pacing5,7 or pacemaker reprogramming to a default
mode.6,31,37 Although it is not known how fre-
quently this occurs, large amounts of electrical
energy during electrosurgery could interfere with a
pacemaker’s pulse generator, damaging the internal
device circuitry. There are rare reports of energy
transfer to the myocardium through the pacer lead,
resulting in thermal damage at the lead–tissue inter-
face.26,29,31,32,37,40 Because the energy levels
encountered in most office dermasurgical suites is
not commonly associated with these reported inter-
ferences, the exact frequency of EMI with IEDs in an
office dermasurgery practice is not known.
Attempts to lessen the effects of EMI on pacemakers
have included metallic shielding to protect against
high-frequency EMI; noise sampling periods con-
verting pacemakers to a fixed rate if continuing EMI
is sensed; bipolar leads, which have improved the
rejection of noise over the original unipolar lead41;
and ‘‘bandpass filters’’ filtering nonphysiologic sig-
nals outside the narrow range of cardiac depolar-
ization frequencies.5,31 These improvements have
significantly reduced the frequency of EMI events
with cardiac devices.42
Pacemaker-dependent patients are a special sub-
group to analyze before electrosurgery. Patients who
have no underlying rhythm other than the paced
rhythm are considered pacemaker dependent and
should be identified, because prolonged inhibition of
a paced rhythm could lead to symptoms. Roughly
5% to 10% of patients with implantable cardiac
pacemakers are dependent on the device for main-
taining adequate heart rhythm.34,42,43 Only the
cardiologist or device representative may know this
status. Asynchronous pacing is thought to minimize
the potential for reversion or inhibition due to
oversensing. Although this preoperative program-
ming change is standard for pacemaker-dependent
patients, complications have been reported. One
report described EMI from a monopolar device caus-
ing battery depletion and eventual ‘‘voltage control
oscillator lock-out,’’ with subsequent pacemaker
failure in a 15-year-old patient after cardiac surgery.2
In a second report, sudden irreversible output loss
after the use of bipolar electrosurgery in short bursts
at a site more than 12 inches from the pulse gener-
ator occurred.44 The generator was subsequently
explanted and found to be functioning in the ‘‘reset’’
mode several weeks later. Initial pacemaker failure
was postulated to be due to a ‘‘voltage control
oscillator lock-out,’’ but it was unknown whether
the pacemaker was functioning in the ‘‘reset’’ mode
because of exposure to cold temperatures during
transport to the manufacturer or to further use of an
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electrosurgical device during explantation. These
rare but dangerous complications highlight the need
even for the office-based dermasurgeon to use
electrosurgical equipment with the least amount of
risk for EMI in patients with cardiac implants. For
this reason, pacemakers and ICDs of known
pacemaker-dependent patients at the University of
Michigan are reprogrammed to an asynchronous
mode before most surgeries requiring electrosurgery
with continuous intraoperative monitoring.34,38
Large Modern Series of EMI in Cardiac Implants
A cross-sectional prospective study of 92 consecutive
patients who underwent noncardiac surgical or endo-
scopic procedures found infrequent cardiac device
malfunction related to EMI.42 Patients underwent pre-
and postoperative interrogation of their pacemakers or
ICDs. Rare inappropriate sensing by devices was
reported with monopolar electrosurgical application in
close proximity to a cardiac implant. All devices with-
stood periprocedural EMI exposure without malfunc-
tion or changes in programming. Only minor changes
in lead parameters were found, along with three devices
resetting briefly to an atrial arrhythmia response mode
(mode switching) and two pacemakers inappropriately
sensing ventricular noise with electrosurgical applica-
tion within 8 cm of the pacemaker generator. These
changes had no immediate clinical detriment.
A retrospective review of 173 patients with a pace-
maker and 13 with an ICD who underwent Mohs or
dermatologic excisional surgery involving electro-
surgery was performed at the Mayo Clinic.45 All
patients had preoperative cardiology evaluation or
device information reviewed by a staff member who
deemed preoperative cardiology consultation
unnecessary. Twelve of the 13 patients with an ICD
underwent preoperative device deactivation with
continuous intraoperative monitoring until post-
operative device reactivation. The remaining patient
with an ICD was advised against electrosurgery due
to pacemaker dependence and therefore received
heat electrocautery for hemostasis. Patients received
bipolar electrosurgery using short bursts of low-
voltage electrical activity. No operation-related de-
vice malfunctions or complications were identified
after postoperative interrogation.45
Academic Medical Center Experience
Despite the favorable outcome reported above, the risk
of EMI is not zero. Until a consensus statement from
large medical societies (such as the Heart Rhythm
Society) is published, our institution has taken a cau-
tious approach, recognizing that these recommenda-
tions may not always be agreed upon or practical for
all office-based procedures. Specific EMI complications
from dermasurgery have not been reported in a high-
level evidence fashion, and until studies on the relative
safety of one method of hemostasis over another are
reported, some simple precautions are made.
Because bipolar electrosurgery and heat electrocautery
have excellent safety profiles, these modalities are con-
sidered optimal.27 Over the past three decades in our
institution, we have not observed any known EMI with
IEDs using this approach. When the risk of bleeding is
high, such as with larger lesions, in vascular locations,
or in patients taking anticoagulants, precautions are
taken. Until data are reported or national guidelines are
published, all ICD patients at our institution are
continuously monitored during electrosurgery, with
emergency pacing and defibrillation equipment readily
available. If the implanted device malfunctions, a longer
time between bursts is implemented to attempt to
minimize hemodynamic effects. The grounding pad is
placed so that current flowing between the surgical site
and the grounding pad will not intersect the pacing
system. Device function is evaluated postoperatively to
identify setting changes that may have occurred
intraoperatively (Medtronic Technical Services,
personal communication, September 2009).2,34
Many industry representatives and cardiologists do
not believe that all devices need to be routinely
evaluated immediately after surgery because there
have been no reported instances of EMI-induced
permanent reprogramming, and it may not be
feasible in all practice settings to obtain an
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evaluation. Should an office-based dermasurgery
proceed because of practical issues, then
electrosurgery should not be performed within 6
inches (15 cm) of a cardiac device or lead system
without prior consultation. Minimum power
settings and short, intermittent, irregular bursts
(o1-second duration) should be used, but interro-
gation should be performed if one suspects any
change of device function or settings have occurred.6
Refer to Figures 3 and 4 for University of Michigan
periprocedural pacemaker and ICD management
algorithms.







Figure 3. University of Michigan periprocedural management for a pacemaker patient for planned, unmonitored office-
based procedures.
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Figure 4. University of Michigan periprocedural management of a patient with an implantable cardioverter defibrillator
(ICD) for planned, unmonitored office-based procedures.
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EMI has the potential to cause irreparable damage to
cochlear devices, necessitating a surgical procedure
for replacement. Electrosurgical instruments are ca-
pable of producing voltages of such magnitude that a
direct coupling can exist between the electrosurgical
tip and a cochlear implant electrode. In addition to
implant damage, sufficient electrical energy could
necrotize vital cells of the basilar membrane, making
re-implantation futile.11 The manufacturer, Med-EL
Corporation, states that monopolar use is strictly
prohibited on any patient with cochlear devices and
supports the use of bipolar electrosurgery as long as
it is kept at least 3 cm from the implant package and
electrodes (S. Greene, personal communication,
September 2009). Further recommendations from
Med-EL include removing all external equipment
before surgical procedures. Active and return electro-
surgical electrodes should not be in the head or
neck region. In addition, precautions should be
taken to prevent flow of electric current over the
head and neck region of the patient. This includes
avoiding conductive underlay or conductive blanket
use and current flow across the head from monitor
cables (S. Greene, personal communication,
September 2009).
Deep Brain Stimulators
Data on the effects of electrosurgery on deep brain
stimulators is limited, but the absence of sound data
does not permit excluding it as a potential health
concern.15 Although EMI does not appear to present
an immediate safety concern in patients with deep
brain stimulators, device malfunction with resulting
temporary interruption in therapeutic benefit may
occur.15 We found only two case reports of Mohs
surgery performed on patients with deep brain stim-
ulators. In one report, hemostasis was obtained using
heat electrocautery without discomfort or complica-
tions.4 The other reported using monopolar electro-
surgery without a grounding pad for hemostasis. The
patient experienced immediate lancinating ‘‘electric
shock’’ sensations down his left arm and leg. Mono-
polar electrosurgery was discontinued, and heat
electrocautery was used for the remainder of the pro-
cedure, without discomfort. Postoperative assessment
did not reveal any changes in device parameters. The
patient required additional dermatologic procedures in
which two different electrosurgical methods were
used. The patient once again experienced electric
shock sensations when a monopolar pencil was used
to achieve hemostasis of a left preauricular lesion with
grounding pad on the right posterior calf. Bipolar
forceps were used in a subsequent procedure without
discomfort. In a third procedure, a monopolar pencil
was once again used for a lesion on the left cheek. The
grounding pad was positioned on the left trapezius, so
that it was closer to the electrical output yet away
from the device. The patient did not report any
discomfort with this arrangement.14
Other Devices
Manufacturers warn that EMI from electrosurgical
application can result in damage to devices and their
components, as well as temporary changes in neuro-
stimulator output, reprogramming, and failure in deep
brain stimulators, vagal nerve stimulators, sacral nerve
stimulators, spinal cord stimulators, and gastric pace-
makers.13,17,46–50 In addition, currents induced in the
lead portion of the neurostimulation system can be
hazardous or cause further injury.48–50 To minimize
these risks, deep brain stimulators, sacral nerve stim-
ulators, spinal cord stimulators, and gastric pace-
makers may be turned off before electrosurgical
application.14,48–50 Deactivation of a vagal nerve
stimulator is not necessary18 and should not be per-
formed in patients with bone stimulators (K. Edwards,
personal communication, October 2009).
Heat electrocautery should be used for these devices
when appropriate, because it poses no risk to the
patient as long as it is used away from the device.
When performing electrosurgery, bipolar is recom-
mended away from the stimulator or lead.46–50 If
monopolar is necessary, a low-voltage mode should
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be used on the lowest possible power setting, keeping
the grounding pad as far from the neurostimulator,
extension, and lead as possible.46–50 A manufacturer
website states that monopolar electrosurgery should
not be used on patients with spinal cord stimula-
tors.8 Care should be taken to avoid electrode
placement that puts a pulse generator or lead in the
direct path of current flow or within the area of the
body being treated.19,49 In addition, cables connect-
ing a lead or extension to an external neurostimu-
lator should be disconnected in sacral nerve
stimulators and spinal cord stimulators.48,50 Finally,
postoperative evaluation of a neurostimulator
should be performed for proper functioning.19,48–50
Our literature search did not reveal any specific rec-
ommendations pertaining to electrosurgery in patients
with phrenic nerve stimulators and bone stimulators.
In addition, specific warnings and recommendations
were not found on manufacturer websites. Personal
communication with manufacturer representatives
revealed a recommendation of bipolar electrosurgery
on patients with phrenic nerve stimulators (K. Aron,
personal communication, September 2009) and
warnings that electrosurgical devices may cause bone
stimulators to be ‘‘shorted out’’ or rendered ineffective
and could result in local tissue damage (K. Edwards,
personal communication, October 2009).
Conclusion
Technological advances have prompted the implan-
tation of a variety of electronic devices for a myriad
of cardiac and neurological disorders that cannot be
managed using medication alone. Encountering
patients with an IED who present for an office-based
procedure is becoming increasingly common.
Potential EMI is a concern for physicians performing
procedures using electrosurgery. Understanding
potential complications when performing electro-
surgery in this group of patients is vital for patient
safety. Device-specific perioperative guidelines are
needed to ensure safety when performing electro-
surgery in patients with modern IEDs. The peri-
operative management of pacemakers and ICDs is a
major focus for organizations such as the Heart
Rhythm Society, which is preparing a document to
address this topic. This will also provide a stimulus
for clinical research to advance our understanding
and improve clinical care.
References
1. Venkatraghavan L, Chinnapa V, Peng P, Brull R. Non-cardiac
implantable electrical devices: brief review and implications for
anesthesiologists. Can J Anesth 2009;56:320–6.
2. Mangar D, Atlas GM, Kane PB. Electrocautery-induced pace-
maker malfunction during surgery. Can J Anesth 1991;38:616–8.
3. Mond HG, Sloman JG, Edwards RH. The first pacemaker. Pacing
Clin Electrophysiol 1982;5:278–82.
4. Martinelli PT, Schulze KE, Nelson BR. Mohs micrographic sur-
gery in a patient with a deep brain stimulator: a review of the
literature on implantable electrical devices. Dermatol Surg
2004;30:1021–30.
5. Yu SS, Tope WD, Grekin RC. Cardiac devices and electromagnetic
interference revisited: new radiofrequency technologies and impli-
cations for dermatologic surgery. Dermatol Surg 2005;31:932–40.
6. Stone ME, Apinis A. Current perioperative management of the
patient with a cardiac rhythm management device. Semin Cardio-
thorac Vasc Anesth 2009;13:31–43.
7. Occhetta E, Bortnik M, Magnani A, Francalacci G, et al. Inap-
propriate implantable cardioverter-defibrillator discharges unrelated
to supraventricular tachyarrhythmias. Europace 2006;8:863–9.
8. Boston Scientific Products [on-line]. Available from: http://
www.bostonscientific.com/Device.bsci/,/method/DevHome/
navRelId/1000.1003/seo.serve Accessed August 26, 2009.
9. Med-EL Corporation [on-line]. Available from: http://www.
medel.com/US/ Accessed August 26, 2009.
10. Cochlear Limited: Introducing Nuclear 5 [on-line]. Available
from: http://products.cochlearamericas.com/cochlear-implants/
our-cochlear-implant-products. Accessed August 26, 2009.
11. Tognola G, Parazzini M, Sibella F, Paglialonga A, et al. Electro-
magnetic interference and cochlear implants. Ann Ist Super Sanita
2007;43:241–7.
12. Levin G, Ortiz AO, Katz DS. Noncardiac implantable pacemakers
and stimulators: current role and radiographic appearance. Am J
Roentgenol 2007;188:984–91.
13. Medtronic for Healthcare Professionals [on-line]. Available from:
http://www.medtronic.com/for-physicians/index.htm. Accessed
August 26, 2009.
14. Weaver J, Kim SJ, Torres A. Cutaneous electrosurgery in a patient
with a deep brain stimulator. Dermatol Surg 1999;25:415–7.
15. Dustin K. Evaluation of electromagnetic incompatibility concerns
for deep brain stimulators. J Neurosci Nurs 2008;40:299–303.
16. Cyberonics, Inc. [on-line]. Available from: http://us.cyberonics.
com/en. Accessed June 10, 2010.
17. Brief Summary of Safety Information for the VNS Therapy Sys-
tem. Available from: http://www.vnstherapy.com/epilepsy/hcp/
indications_for_use.aspx. Accessed August 28, 2009.
D E R M AT O L O G I C S U R G E RY8 9 8
E L E C T R O S U R G E RY A N D I M P L A N TA B L E E L E C T R O N I C D E V I C E S
18. Hatton KW, McLarney JT, Pittman T, Fahy BG. Vagal nerve
stimulation: overview and implications for anesthesiologists.
Anesth Analg 2006;103:1241–9.
19. Physician’s Manual VNS Therapy Demipulse Model 103 Gener-
ator and VNS Therapy Demipulse Duo Model 104 Generator [on-
line]. Available from: http://www.vnstherapy.com/manuals/. Ac-
cessed October 9, 2009.
20. Avery Breathing Pacemakers [on-line]. Available from: http://
www.averylabs.com/index.html. Accessed August 27, 2009.
21. Instruction Manual for the Mark IV Breathing Pacemaker System.
Commack, NY: Avery Biomedical Devices. Inc.; 2009.
22. Zhang J, Chen JD. Systematic review: applications and future of
gastric electrical stimulation. Aliment Pharmacol Ther 2006;
24:991–1002.
23. Hasler WL. Methods of gastric electrical stimulation and pacing:
a review of their benefits and mechanisms of action in gastropa-
resis and obesity. Neurogastroenterol Motil 2009;21:229–43.
24. Kesani AK, Gandhi A, Lin SS. Electrical bone stimulation devices
in foot and ankle surgery: types of devices, scientific basis and
clinical indications for their use. Foot Ankle Int 2006;16:148–56.
25. OsteoGen Bone Growth Stimulator [on-line]. Available from:
http://www.biomet.com/trauma/products.cfm?pdid=4&majcid=
47&prodid=268. Accessed August 28, 2009.
26. LeVasseur JG, Kennard CD, Finley EM, Muse RK, et al. Der-
matologic electrosurgery in patients with implantable card-
ioverter-defibrillators and pacemakers. Dermatol Surg
1998;24:233–40.
27. El-Gamal HM, Dufresne RG, Saddler K. Electrosurgery, pacemak-
ers and ICDs: a survey of precautions and complications experi-
enced by cutaneous surgeons. Dermatol Surg 2001;27:385–90.
28. Dyrda K, Khairy P. Implantable rhythm devices and electro-
magnetic interference: myth or reality? Expert Rev Cardiovasc
Ther 2008;6:823–32.
29. Sweesy MW. Understanding electromagnetic interference. Heart
Rhythm 2004;4:523–4.
30. Kolb C, Zrenner B, Schmitt C. Incidence of electromagnetic in-
terference in implantable cardioverter defibrillators. Pacing Clin
Electrophysiol 2001;24(4 Pt 1):465–8.
31. Madigan JD, Choudhri AF, Chen J, Spotnitz HM, et al. Surgical
management of the patient with an implanted cardiac device. Ann
Surg 1999;230:639–47.
32. Yerra L, Reddy PC. Effects of electromagnetic interference on
implanted cardiac devices and their management. Cardiol Rev
2007;15:304–9.
33. Magnet Use for Suspending Medtronic ICD Detection [on-line].
Available from: http://cacgas.com/uploads/Medtronic___Magnet_
use_and_ICD.pdf. Accessed September 8, 2009.
34. Dawes JC, Mahabir RC, Hillier K, Cassidy M, et al. Electrosur-
gery in patients with pacemakers/implanted cardioverter defibril-
lators. Ann Plast Surg 2006;57:33–6.
35. Wolbrette DL, Naccarelli GV. Management of implantable cardio-
verter defibrillator patients: role of predischarge electrophysiologic
testing and proper patient instruction before hospital discharge. Curr
Opin Cardiol 2001;16:72–5.
36. Hazelton GA, Sears SF, Kirian K, Matchett M, et al. Coping with
my partner’s ICD and cardiac disease. Circulation 2009;120:e73–6.
37. Sweesy MW, Holland JL, Smith KW. Electromagnetic interference
in cardiac rhythm management devices. AACN Clin Issues
2004;15:391–403.
38. Niehaus M, Tebbenjohanns J. Electromagnetic interference in
patients with implanted pacemakers or cardioveter-defibrillators.
Heart 2001;86:246–8.
39. Heller LI. Surgical electrocautery and the runaway pacemaker
syndrome. Pacing Clin Electrophysiol 1990;13:1084–5.
40. Snow JS, Kalenderian D, Colasacco JA, Jadonath RL, et al. Im-
planted devices and electromagnetic interference: case presenta-
tions and review. J Invasive Cardiol 1995;7:25–32.
41. Wilson S, Neustein SN, Camunas J. Rapid ventricular pacing due
to electrocautery: a case report and review. Mt Sinai J Med
2006;73:880–3.
42. Cheng A, Nazarian S, Spragg D, Bilchick K, et al. Effects of sur-
gical and endoscopic electrocautery on modern-day permanent
pacemaker and implantable cardioverter-defibrillator systems.
Pacing Clin Electrophysiol 2008;31:344–50.
43. Nanthakumar K, Dorian P, Ham M, Lam P, et al. When pace-
makers fail: an analysis of clinical presentation and risk in 120
patients with failed devices. Pacing Clin Electrophysiol
1998;21:87–93.
44. Peters RW, Gold MR. Reversible prolonged pacemaker failure due
to electrocautery. J Interv Card Electrophysiol 1998;2:343–4.
45. Matzke TJ, Christenson LJ, Christenson SD, Atanashova N, et al.
Pacemakers and implantable cardiac defibrillators in dermato-
logic surgery. Dermatol Surg 2006;32:1155–62.
46. Technical Manual for Kinetra Dual Program Neurostimulator for




47. Physician and Hospital Staff Manual for Soletra Neurostimulator




48. InterStim Therapy Information for Prescribers [on-line]. Available
from: http://professional.medtronic.com/products/interstim-
sacral-nerve-neurostimulator/manuals-and-technical-resources/
index.htm#tab3. Accessed September 10, 2009.
49. Technical Manual for Enterra Therapy Gastric Electrical Stimu-
lation System [on-line]. Available from: http://professional.med
tronic.com/products/enterra-gastric-neurostimulator/manuals-
and-technical-resources/index.htm. Accessed September 10, 2009.
50. Medtronic Pain Therapy: Information for Prescribers [on-line].
Available from: http://professional.medtronic.com/products/
restoreadvanced-spinal-cord-neurostimulator/manuals-and-tech
nical-resources/index.htm#tab3. Accessed September 10, 2009.
Address correspondence and reprint requests to: Melissa
A. Voutsalath, DO, University of Michigan Health System,
1147 Cancer and Geriatrics Center, 1500 E. Medical
Center Drive, Ann Arbor, MI 48109-0918, or e-mail:
mvoutsal@med.umich.edu
3 7 : 7 : J U LY 2 0 1 1 8 9 9
V O U T S A L AT H E T A L
